The 2022-2027 Strategic Agreement between the Commonwealth and Medicines Australia included a commitment to Co-design an Enhanced Consumer Engagement Process. A Co-Design Working Group consulted on draft recommendations for how consumers and patients can be included earlier in health technology assessment (HTA) and the medicines listing process in Australia. Australian Genomics’ submission supported all recommendations, and highlighted that consumers have a right to be involved as early as possible, and the need to develop a transparent framework for including and weighting consumer evidence in HTA processes.
